Европска Унија - Мелтешки - EMA (European Medicines Agency)

mylan pharmaceuticals limited - deferasirox - iron overload; beta-thalassemia - aġenti kelanti tal-ħadid - deferasirox mylan huwa indikat għall-kura ta 'tagħbija żejda kronika tal-ħadid minħabba trasfużjonijiet tad-demm frekwenti (≥7 ml/kg/xahar ta' ċelloli ħomor ippakkjati) f'pazjenti bil-beta talassemija maġġuri ta '6 snin u l-olderthe-trattament tal-eċċess kroniku ta'ħadid minħabba trasfużjonijiet tad-demm meta terapija b'deferoxamine tkun kontra-indikata jew inadegwata f'dawn gruppi ta' pazjenti:f'pazjenti pedjatriċi b'beta-talessimja maġġuri b'tagħbija żejda tal-ħadid minħabba trasfużjonijiet tad-demm frekwenti (≥7 ml/kg/xahar ta ' ċelloli ħomor ippakkjati) b'età minn 2 sa 5 snin,fl-adulti u f'pazjenti pedjatriċi bil-beta talassemija maġġuri b'tagħbija żejda tal-ħadid minħabba trasfużjonijiet tad-demm frekwenti (.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

jazz pharmaceuticals ireland limited - cannabidiol - lennox gastaut syndrome; epilepsies, myoclonic - anti-epilettiċi, - epidyolex huwa indikat għall-użu bħala terapija aġġuntiva ta 'aċċessjonijiet assoċjati mas-sindrome lennox gastaut (lgs) jew sindromu ta'dravet (ds), flimkien ma' clobazam, għall-pazjenti 2 snin ta ' età u anzjani.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

vanda pharmaceuticals ltd - iloperidone - skizofrenija - psikolettiċi - il-kura ta ' skizofrenja.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

merz pharmaceuticals gmbh - memantine hydrochloride, donepezil hydrochloride - marda ta 'alzheimer

Европска Унија - Мелтешки - EMA (European Medicines Agency)

mylan pharmaceuticals limited - acetylsalicylic acid, clopidogrel hydrogen sulfate - acute coronary syndrome; myocardial infarction - aġenti antitrombotiċi - clopidogrel/acetylsalicylic acid mylan huwa indikat għall-prevenzjoni sekondarja ta ' avvenimenti aterotrombotiċi f'pazjenti adulti li diġà qed jieħdu ż-żewġ clopidogrel u acetylsalicylic acid (asa). clopidogrel/acetylsalicylic acid mylan huwa kombinazzjoni b'doża fissa tal-prodott mediċinali għall-kontinwazzjoni tat-terapija:mhux elevazzjoni tas-segment st sindromu koronarju akut (anġina instabbli jew mhux-mewġa-q infart mijokardijaku) li jinkludu pazjenti fi proċess li titpoġġa stent wara koronarju perkutanju interventionst elevazzjoni tas-segment infart mijokardijaku akut fil-medikament pazjenti kkurati b'eliġibbli għat-terapija trombolitika.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - fibrożi ċistika - prodotti oħra tas-sistema respiratorja - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - sera immuni u immunoglobulini, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - thiotepa - hematopoietic stem cell transplantation; neoplasms - aġenti antineoplastiċi - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

amarin pharmaceuticals ireland limited - icosapent ethyl - dyslipidemias - aġenti li jimmodifikaw il-lipidi - indicated to reduce cardiovascular risk as an adjunct to statin therapy.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - tumur stromali gastrointestinali - aġenti antineoplastiċi - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.